The $3.4 Billion Lesson Pharma Faces in Shelved Drugs
Thousands of shelved drug candidates could unlock therapies for rare diseases, but funding and partnerships lag. The ...
Short on time? Check out these ways to make money in 5 minutes that can help you earn extra cash quickly.
13,498 articlesThousands of shelved drug candidates could unlock therapies for rare diseases, but funding and partnerships lag. The ...
CF Industries has surged this year on supply constraints and cost advantages, yet a DOJ probe adds regulatory risk th...
This week brought a sharp 19% drop in first majestic silver corporation shares. In this article, we break down the ma...
When a stock plunges, investors face a fork in the road: fear or opportunity. This guide breaks down how to evaluate ...
Copper demand is surging as data centers, EVs, and renewables push miners to expand. BHP reorganizes around copper, w...
A late-2025 Gallup poll finds only 28% of workers say now is a good time to find a quality job, with broad caution do...
In 2026, breadth returns as equal-weight ETFs beat the S&P 500, nudging investors toward diversified exposure. Here a...
Microsoft is staring down a tough start to the year. Is the slide a red flag or a rare chance to buy a tech titan wit...
A fresh pullback can create smart entry points. This guide highlights my top 3 financial stocks after latest market p...
Broadcom stands at a pivotal crossroads as AI spending shifts from pilots to production. This article lays out the ke...
As JJSF prepares for its 2026 earnings call, investors will scrutinize margins, pricing power, and capital allocation...
When a senior executive at Maze Therapeutics sells a stake after positive trial data and solid quarterly results, inv...